We hope that in the future, more prospective articles will be added to analyze whether 18F-DCFPyL PSMA PET can be used as a diagnostic tool to avoid prostate biopsy in patients with primary prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.